US Patent

US11319346 — Ultra-pure agonists of guanylate cyclase C, method of making and using same

Formulation · Assigned to Bausch Health Ireland Ltd · Expires 2032-03-01 · 6y remaining

Vulnerability score 39/100 Strong — defensible against typical IPR challenges

What this patent protects

This patent protects processes for purifying a peptide that acts as an agonist of guanylate cyclase C, including a solvent exchange and freeze-drying step.

USPTO Abstract

The invention provides processes of purifying a peptide including a GCC agonist sequence selected from the group consisting of SEQ ID NOs: 1-251 described herein. The processes include a solvent exchange step before a freeze-drying (lyophilization) step.

Drugs covered by this patent

Patent Metadata

Patent number
US11319346
Jurisdiction
US
Classification
Formulation
Expires
2032-03-01
Drug substance claim
No
Drug product claim
Yes
Assignee
Bausch Health Ireland Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.